Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Michel Pavic, Meral Beksaç et al.|The Lancet|2019Cited by 635
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trialAttaya Suvannasankha, Alexander M. Lesokhin, Jonathan L. Kaufman et al.|Blood|2025Cited by 6